

~~16.~~ A composition as claimed in claim ~~12~~ presented in the form of a metered dose inhaler or a metered dry powder composition.--

~~14~~  
~~1482~~ ~~17.~~ A composition as claimed in claim ~~13~~ in dosage unit form comprising 25-100  $\mu$ g of the 1-hydroxy-2-naphthalenecarboxylate salt of salmeterol and 25-500  $\mu$ g of fluticasone propionate per dosage unit.--

~~18.~~ A composition as claimed in claim ~~14~~ presented in the form of a metered dose inhaler or a metered dry powder composition.--

*C1*  
*Continued* ~~19.~~ The use of salmeterol or a physiologically acceptable salt thereof and fluticasone propionate in the manufacture of pharmaceutical compositions as combined preparations for simultaneous, sequential or separate administration of salmeterol and fluticasone propionate by inhalation in the treatment of respiratory disorders.--

~~20.~~ A method of treating respiratory disorders which comprises the simultaneous, sequential or separate administration by inhalation of effective amounts of salmeterol or a physiologically acceptable salt thereof and fluticasone propionate.--

~~10~~ ~~21.~~ A method as claimed in claim ~~20~~ wherein the salmeterol or a physiologically acceptable salt thereof and the fluticasone propionate are administered on a twice daily basis.--

~~1482~~  
~~LL~~ ~~22.~~ A method as claimed in claim ~~21~~ wherein the effective amount of salmeterol or a physiologically acceptable salt thereof is 50-200  $\mu$ g per day and the effective amount of fluticasone propionate is 50-1000  $\mu$ g per day.--

*EWD*  
REMARKS

Applicant has amended the claims in consideration of the comments contained in the Official Action dated April 1, 1991, in parent application serial number 07/578,601. All of the claims in the application have been cancelled in favor of new claims 12-22,